No Detail Found!

Biologic management of fistulizing Crohn’s Disease.

Author(s)
Ali Rezaie Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran
Bardia Taghavi Bayat Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran
Mohammad Abdollahi Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran
Abstract
Fistulas, occurring in about 20 to 40% of Crohn’s disease patients, are usually resistant to conventional therapy of CD. Biologic therapies, which have revolutionary beneficial effects on diseases with an immunologic background, are a new horizon in treating fistulizing CD. The aim of this study was to evaluate the efficacy of biologic agents used to treat fistulizing CD after a brief overview on epidemiology and pathophysiology of fistulizing CD and definition of biologic therapy. Also it focuses on the trials and adverse effects of the biologic agents proved to be effective (Infliximab and CDP571).
Publication Details
Page(s) 17-24
DOI DOI not available
Published Journal: International Journal of Pharmacology, Volume: 1, Issue: 1, Year: 2005

Request the full text from PASTIC

0

Citations

0

Downloads

54

Views